



wherein: X is a linker selected from the group consisting of C_1 - C_6 alkylene, C_2 - C_6 alkenylene, or C_3 - C_6 alkynylene, wherein X may optionally include 1 or 2 oxygen atoms and/or 1 sulfur atom;

Y is a group pendant from X, wherein Y is a C_1 - C_{10} alkyl, C_2 - C_{10} alkenyl, C_2 - C_{10} alkynyl, aromatic or cyclic-aliphatic group to which is attached at least one $-OSO_3R^4$ moiety, and, optionally, at least one OH group, wherein R^4 is H or a pharmaceutically acceptable cation; or,

Y is $-OSO_3R^4$, wherein R^4 is H or a pharmaceutically acceptable cation;

N is an integer from 1-3; and

R^1 and R^2 are each independently selected from the group consisting of -H, a halogen with an atomic number from 9 to 53, hydroxy, $-SO_3R^4$, $-OSO_3R^4$, -NCS, -NCO, $-NH(CO)-OR^3$, $-NH(CS)SR^3$, $-NH(C=NH)OR^3$, $-NHCOCH_2Cl$, $-NHCOCH_2Br$, $-NHCO-CH=CH_2$, $-NHC(O)-CF_3$, $-S-CH_2-CH=CH_2$, $-NHCH_2-C\equiv CH$, $-NH-CH_2-CN$, $-NH-S-CH_2-CH=CH_2$, $-O-CH_2-CH=CH_2$, $-NH-CF_3$, N-mono-, di-, tri-, tetra- and penta-haloethyl, -CN, $-NH_2$, $-NO_2$, $-NHCOCH_3$, -CHO, $-COOR^4$, $-N_3$, $-COR^3$, $-R^3OH$, $-R^3NHCOCH_3$, $-R^3OSO_3R^4$, $-R^3SO_3R^4$, $-OR^3$, $-SR^3$ and $-R^3$, wherein $-R^3$ is p-nitrophenyl, C_1 - C_6 alkyl, C_2 - C_6 alkenyl, or C_2 - C_6 alkynyl, if at the distal end of the substituent, or C_1 - C_6 alkylene, C_2 - C_6 alkenylene, or C_2 - C_6 alkynylene, if at the proximal end of the substituent, and wherein R^4 is H or a pharmaceutically acceptable cation.

Please cancel claims 1-27 and 40 without prejudice or disclaimer.

REMARKS

Claims 1-40 are pending in this application. Claims 1-27 and 40 have been withdrawn from consideration as being drawn to a non-elected invention. Claims 28-39 are rejected. By